Monte Rosa Q1 net loss $23.9M; IND for MRT-2359 expected mid-2022

Monte Rosa Therapeutics, Inc.

Net loss $23.9M for Q1 2022 vs $12.3M in Q1 2021; R&D spend $17.9M.
Cash position $322.5M as of March 31, 2022; runway into late 2024.
IND submission for GSPT1 degrader MRT-2359 on track for mid-2022; initial focus on NSCLC and SCLC.
Preclinical data at AACR 2022 support MRT-2359 in Myc-driven solid tumors.
New collaboration with EPFL to integrate AI engine with MaSIF technology for novel degrader discovery.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.